膜转运体的药物基因组学项目：基因组学与转运体药理学的交叉研究。
The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology.
机构信息
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
出版信息
Clin Pharmacol Ther. 2010 Jan;87(1):109-16. doi: 10.1038/clpt.2009.226. Epub 2009 Nov 25.
Abstract
Since the cloning of the first membrane transporter, our understanding of the role of transporters in clinical drug disposition and response has grown enormously. In parallel, large-scale genome-wide variation studies and the emerging field of pharmacogenomics have ushered in a new understanding of variations in drug response. At the crossroads of pharmacogenomics and transporter biology is the National Institutes of Health-funded Pharmacogenomics of Membrane Transporters (PMT) project, centered at the University of California, San Francisco.
摘要
自从克隆出第一个膜转运蛋白以来，我们对转运蛋白在临床药物处置和反应中的作用的理解已经有了巨大的发展。与此同时，大规模的全基因组变异研究和新兴的药物基因组学领域也使我们对药物反应的变异有了新的认识。药物基因组学和转运蛋白生物学的交汇点是美国国立卫生研究院资助的膜转运蛋白（PMT）项目，该项目以加利福尼亚大学旧金山分校为中心。
相似文献
1
The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology.膜转运体的药物基因组学项目：基因组学与转运体药理学的交叉研究。
Clin Pharmacol Ther. 2010 Jan;87(1):109-16. doi: 10.1038/clpt.2009.226. Epub 2009 Nov 25.
2
Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy.机构简介：加州大学药物基因组学中心：基因组学、生物机制与药物治疗的交汇点。
Pharmacogenomics. 2009 Oct;10(10):1569-76. doi: 10.2217/pgs.09.119.
3
Pharmacogenomics of membrane transporters: past, present and future.膜转运体的药物基因组学：过去、现在和未来。
Pharmacogenomics. 2010 Apr;11(4):475-9. doi: 10.2217/pgs.10.22.
4
Pharmacogenomics and systems biology of membrane transporters.膜转运蛋白的药物基因组学与系统生物学
Mol Biotechnol. 2005 Jan;29(1):75-88. doi: 10.1385/MB:29:1:75.
5
Pharmacogenetics and pharmacogenomics in the discovery and development of medicines.药物遗传学与药物基因组学在药物发现与开发中的应用
Novartis Found Symp. 2000;229:63-6; discussion 66-70. doi: 10.1002/047084664x.ch9.
6
Pharmacogenetics, pharmacogenomics and airway disease.药物遗传学、药物基因组学与气道疾病
Respir Res. 2002;3(1):10. doi: 10.1186/rr159. Epub 2001 Nov 26.
7
Pharmacogenetics and pharmacogenomics: development, science, and translation.药物遗传学与药物基因组学：发展、科学与转化
Annu Rev Genomics Hum Genet. 2006;7:223-45. doi: 10.1146/annurev.genom.6.080604.162315.
8
SNP analysis and presentation in the Pharmacogenetics of Membrane Transporters Project.膜转运体药物遗传学项目中的单核苷酸多态性分析与展示
Pac Symp Biocomput. 2003:535-47.
9
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine.药物代谢酶和转运体的药物基因组学：与精准医学的相关性
Genomics Proteomics Bioinformatics. 2016 Oct;14(5):298-313. doi: 10.1016/j.gpb.2016.03.008. Epub 2016 Oct 8.
10
Human membrane transporter database: a Web-accessible relational database for drug transport studies and pharmacogenomics.人类膜转运体数据库：一个可通过网络访问的关系型数据库，用于药物转运研究和药物基因组学。
AAPS PharmSci. 2000;2(3):E20. doi: 10.1208/ps020320.
引用本文的文献
1
Determinants in Tailoring Antidiabetic Therapies: A Personalized Approach.定制抗糖尿病疗法的决定因素：个性化方法
Glob Med Genet. 2022 Jun 13;9(2):63-71. doi: 10.1055/s-0041-1741109. eCollection 2022 Jun.
2
A critical review on modulators of Multidrug Resistance Protein 1 in cancer cells.关于癌细胞中多药耐药蛋白 1 调节剂的综述评价。
PeerJ. 2022 Jan 5;10:e12594. doi: 10.7717/peerj.12594. eCollection 2022.
3
..
Drug Metab Dispos. 2021 Dec 17;50(9):1193-210. doi: 10.1124/dmd.121.000702.
4
Diffusion Mechanism Modeling of Metformin in Human Organic Cationic Amino Acid Transporter one and Functional Impact of S189L, R206C, and G401S Mutation.二甲双胍在人有机阳离子氨基酸转运体1中的扩散机制建模以及S189L、R206C和G401S突变的功能影响
Front Pharmacol. 2021 Feb 9;11:587590. doi: 10.3389/fphar.2020.587590. eCollection 2020.
5
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.遗传多态性对有机阳离子转运体的影响与肾脏药物处置。
Int J Mol Sci. 2020 Sep 10;21(18):6627. doi: 10.3390/ijms21186627.
6
Toxicology Data Resources to Support Read-Across and (Q)SAR.支持类推和（定量）构效关系的毒理学数据资源。
Front Pharmacol. 2019 Jun 11;10:561. doi: 10.3389/fphar.2019.00561. eCollection 2019.
7
Pharmacogenetic variation influences sensory neuropathy occurrence in Southern Africans treated with stavudine-containing antiretroviral therapy.遗传药理学变异影响含司他夫定的抗逆转录病毒治疗的南非裔人群中感觉性周围神经病的发生。
PLoS One. 2018 Oct 1;13(10):e0204111. doi: 10.1371/journal.pone.0204111. eCollection 2018.
8
Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.转运蛋白多态性对药物处置和反应的影响：来自国际转运蛋白联合会的观点。
Clin Pharmacol Ther. 2018 Nov;104(5):803-817. doi: 10.1002/cpt.1098. Epub 2018 May 31.
9
Rare Variants in the Promoter Modulate In Vivo Activity.启动子中的罕见变异可调节体内活性。
Drug Metab Dispos. 2018 May;46(5):636-642. doi: 10.1124/dmd.117.079541. Epub 2018 Feb 21.
10
ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression.ABCG2调控单核苷酸多态性改变体内增强子活性和表达。
Pharmacogenet Genomics. 2017 Dec;27(12):454-463. doi: 10.1097/FPC.0000000000000312.
本文引用的文献
1
Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1.人转运蛋白MATE1基础启动子区新多态性的鉴定与特征分析
Pharmacogenet Genomics. 2009 Oct;19(10):770-80. doi: 10.1097/FPC.0b013e328330eeca.
2
Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation.ABCA 和 SLCA 超家族近端启动子的遗传变异：肝脏和肾脏特异性表达和启动子活性预测变异。
PLoS One. 2009 Sep 9;4(9):e6942. doi: 10.1371/journal.pone.0006942.
3
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.有机阳离子转运体2基因变异对二甲双胍肾脏排泄的影响。
Pharmacogenet Genomics. 2009 Jul;19(7):497-504. doi: 10.1097/FPC.0b013e32832cc7e9.
4
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.伊立替康所致中性粒细胞减少症及药代动力学的综合药物遗传学分析
J Clin Oncol. 2009 Jun 1;27(16):2604-14. doi: 10.1200/JCO.2008.20.6300. Epub 2009 Apr 6.
5
Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function.多药及毒性化合物外排蛋白1（hMATE1）中的基因变异会改变转运功能。
Pharmacogenomics J. 2009 Apr;9(2):127-36. doi: 10.1038/tpj.2008.19. Epub 2009 Jan 27.
6
Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).有机阳离子/肉碱转运体OCTN1（SLC22A4）和OCTN2（SLC22A5）基础启动子中的功能基因变异。
J Pharmacol Exp Ther. 2009 Apr;329(1):262-71. doi: 10.1124/jpet.108.146449. Epub 2009 Jan 13.
7
Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2).人浓缩核苷转运体2（SLC28A2）近端启动子多态性的鉴定与特征分析。
J Pharmacol Exp Ther. 2009 Mar;328(3):699-707. doi: 10.1124/jpet.108.147207. Epub 2008 Dec 19.
8
Selecting optimum eukaryotic integral membrane proteins for structure determination by rapid expression and solubilization screening.通过快速表达和增溶筛选选择用于结构测定的最佳真核生物整合膜蛋白。
J Mol Biol. 2009 Jan 23;385(3):820-30. doi: 10.1016/j.jmb.2008.11.021. Epub 2008 Nov 24.
9
The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.人类多药耐药蛋白4（MRP4，ABCC4）：一个高度多态性基因的功能分析
J Pharmacol Exp Ther. 2008 Jun;325(3):859-68. doi: 10.1124/jpet.108.136523. Epub 2008 Mar 25.
10
Substrate-dependent effects of human ABCB1 coding polymorphisms.人类ABCB1编码多态性的底物依赖性效应。
J Pharmacol Exp Ther. 2008 May;325(2):435-42. doi: 10.1124/jpet.107.135194. Epub 2008 Feb 20.
Zotero 插件